AstraZeneca’s new weight-loss pill, AZD5004, shows promise in early trials with tolerable side effects, advancing to Phase II studies focused on reducing obesity.
AstraZeneca reported on Monday that its experimental weight-loss pill, AZD5004, licensed from China's Eccogene for up to $2 billion, was found safe and tolerable in an early-stage trial.
The study, which included 72 participants who were either healthy or had type 2 diabetes, showed side effects consistent with other GLP-1 drugs, such as nausea and vomiting. Based on these findings, AstraZeneca has advanced AZD5004 to Phase II trials focused on weight reduction in overweight and obese individuals, with completion expected by late 2025.
Unlike injectable treatments from competitors Eli Lilly and Novo Nordisk, AZD5004 is a small molecule pill that can be combined with other medications and taken with or without food, offering potential advantages for patients with additional health conditions.
AstraZeneca also shared early-stage data on other obesity drugs, AZD6234 and AZD9550, which target different hunger-related hormones and will undergo further Phase II testing through 2026.
Meanwhile, Viking Therapeutics released early trial results for its own oral obesity drug, which briefly boosted its stock before a decline.
Ship traffic through the Bab el-Mandeb Strait fell to its lowest level in months on Sunday after Yemen's Houthi movement attacked Saudi oil facilities...
Indonesian President Prabowo Subianto's approval rating has fallen to 51.1% in July 2026, according to a new poll, with growing concern over the count...
Oil prices have fallen more than six per cent as a pause in U.S.-Iran hostilities eased fears of wider supply disruption around the Gulf....
Russian authorities said 11 people, including four children, had been killed by Ukraine in an overnight attack on a holiday camp, accusing Kyiv on Saturday of deliberately targeting civilians.
Iran will halt its own attacks as long as the United States maintains its pause on strikes, but Tehran remains sceptical of U.S. intentions, a senior Iranian source told on Sunday.
Marvel Studios used its return to San Diego Comic-Con to reveal several major projects, including a new Ghost Rider film starring Ryan Gosling and the long-awaited Black Panther 3.
Kazakhstan's President Kassym-Jomart Tokayev called on Saturday for Russia and Ukraine to freeze the conflict and return to peace talks, saying a negotiated settlement remained possible despite the entrenched positions of both sides.
U.S. President Donald Trump says Israeli Prime Minister Benjamin Netanyahu will visit Washington next week as tensions continue to rise across the Middle East.
A global shift towards healthier diets, more efficient farming and reduced food waste could cut greenhouse gas emissions from agriculture-related land-use change by 85% by 2050, according to a study published last week in the journal Nature.
Venezuelan health authorities have confirmed that three people have died from hantavirus infections, while stressing there is no evidence that the disease is spreading between people in the country.
Up to five cups of caffeinated coffee a day appears to be safe for most adults and may even help protect against heart disease and stroke, according to new research. Experts say energy drinks are a different story and may increase heart risks.
Portugal has become the first European Union member state to join HealthAI's Global Regulatory Network (GRN), as Europe prepares to implement new rules governing artificial intelligence across the bloc.
Nearly 7,000 people across the United States may have been infected with cyclosporiasis, a foodborne parasitic illness that causes prolonged diarrhoea. The outbreak has spread to 34 states, with health officials still trying to identify its source.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment